Latest News
Palisade Bio, Inc.
- Form 4 Palisade Bio Inc: Julien E. Capers (Officer) For: 19 October
- Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data
- Palisade Bio reports early-stage Crohn’s disease trial results By Investing.com
- Palisade Bio Presents Rapid Endoscopic Improvement and New
- Palisade Bio presents clinical data on ulcerative colitis drug By Investing.com
- Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
- Form 4 Palisade Bio Inc For: 11 October By Investing.com
- Palisade Bio director buys $28,800 in PALI stock
- Palisade Bio stock initiated at Outperform by Raymond James
- Palisade Bio (PALI) Holds Above $1.37 Support as Shares Edge Up 0.70% to $1.44 - Long Short Pair
- Palisade Bio to Present Clinical and Translational Data for
- Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Headlines from the last 30 days, linking to the original publishers. See all market news →